There are therapies directed against CGRP and its receptor with proven effects in headache and migraine such as gepants (rimegepant, ubrogepant, atogepant) and monoclonal antibodies (erunumab, fremanezumab, galcanezumab, eptinezumab) [73]. The gene discussed is CALCA; the disease is migraine disorder.